MRKR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
-100.0%
1.1M
-10.5%
1.2M
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
-100.0%
1.1M
-10.5%
1.2M
0
Operating Expenses
2.6M
-35.7%
4.1M
+36.3%
3.0M
-11.3%
3.4M
-34.2%
5.1M
R&D
1.5M
-48.1%
2.8M
+32.8%
2.1M
-8.7%
2.3M
-43.8%
4.2M
SG&A
1.1M
-7.0%
1.2M
+45.3%
846.6K
-17.3%
1.0M
+8.3%
945.2K
Operating Income
-2620366
+35.7%
-4072535
-116.2%
-1883994
+11.8%
-2136726
+58.3%
-5122217
EBITDA
-2620366
+35.7%
-4072535
-116.2%
-1883994
+11.8%
-2136726
+58.3%
-5122217
Net Income
-1826229
+42.6%
-3179278
-86.7%
-1703210
+14.8%
-1998662
+50.2%
-4015564
EPS (Basic)
$-0.09
+43.8%
$-0.16
-77.8%
$-0.09
+25.0%
$-0.12
+58.6%
$-0.29
EPS (Diluted)
$-0.09
+43.8%
$-0.16
-77.8%
$-0.09
+25.0%
$-0.12
+58.6%
$-0.29
Shares (Diluted)
19.3M
+0.0%
19.3M
-0.5%
19.4M
+15.9%
16.8M
+20.1%
14.0M
Marker Therapeutics (MRKR) โ€” Financials